Simple Summary Early-stage disease non-small cell lung cancer has better outcomes than
advanced disease, but 5-year survival rates can drop to approximately 50% in cases of …

More and more clinical trials have explored the role of liquid biopsy in the diagnosis and
treatment of EGFR-mutated NSCLC. In certain circumstances, liquid biopsy has unique …

Purpose The treatment for unresectable, locally advanced stage III non-small cell lung
cancer (NSCLC) is concurrent chemoradiation therapy (CRT) followed by consolidation …

Background Next-generation sequencing (NGS) of plasma cell-free DNA identifies driver
mutations in advanced non-small cell lung cancer (NSCLC) and may complement routine …

Simple Summary Cancer care is being increasingly driven by biomarker testing. Many
biomarkers are traditionally measured on a sample from a patient tumor such as a biopsy …

Objective Liquid biopsy (LB) is a non-invasive technique to detect genetic alterations by next-
generation sequencing (NGS) when tissue biopsy is not available. This study aims to …

The identification of actionable oncogenic driver mutations in patients with non-small cell
lung cancer impacts therapy selection, and appropriate therapy administration results in …

In this thesis, we explore the design, development, and application of nanonetworks within a
human capillary, aiming to revolutionize early detection mechanisms for chronic diseases …